Treatment

This section covers the management of CAD and PAD, looking at guideline recommendations and revascularization procedures

In this section:

Guideline recommendations

Management of CAD and PAD can be challenging.

  • Patients who have both diseases together are at higher risk of morbidity and mortality, and aggressive management strategies are recommended
  • Patients with both CAD and PAD frequently experience poorer hospital outcomes compared with patients with CAD alone

The European Society of Cardiology (ESC) guidelines state that management should include lifestyle advice, patient education, pharmacological therapy and/or revascularization.

Lifestyle advice can reduce several risk factors for cardiovascular disease and includes:

  • Not smoking, taking regular exercise, maintaining a healthy weight and eating a balanced diet
  • A diet low in saturated fats and salt, high in fruit and vegetables and to include a moderate intake of oily fish

Pharmacological management of CAD includes:

  • Short-acting nitrates, beta blockers and/or calcium channel blockers as first-line therapy for angina/ischaemia relief
  • Low-dose ASA and statins, with an angiotensin-converting-enzyme inhibitor if co-morbidities are present (e.g. diabetes, heart failure, hypertension)

Even with appropriate therapies, patients with co-morbidities may still be at an increased risk of cardiovascular events. For example, patients with diabetes had a 2.9-fold higher risk of cardiovascular events despite receiving patient education on reducing their risk of secondary events and drug prescription after ACS versus patients with CAD alone (18-month follow-up).

Medical management of stable CAD

Medical management of stable CAD
aData for diabetics; bif intolerance, consider clopidogrel
ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CCS, Canadian Cardiovascular Society; DHP, dihydropyridine

Revascularization procedures

CABG and PCI are the two main forms of revascularization procedures:

  • Revascularization decisions are based on the presence of significant obstructive coronary artery stenosis and related ischaemia (e.g. post-MI, left ventricular dysfunction), current symptoms and expected benefit
  • Revascularization is recommended if the patient has any significant stenosis (>50%) or a large area of ischaemia
  • PCI is associated with a low mortality risk of <0.5% in stable CAD patients; however, poorer outcomes are expected if lower-extremity PAD is also present
  • Patients with stable CAD undergoing PCI are also recommended to have anticoagulant and antiplatelet therapy


Next section: Special Populations

Approval No.: G.MKT.GM.XA.08.2016.1047

Was this helpful?

Yes No

Sorry to hear that. Please tell us how we can improve (step 2/2)

Your comments will not be shared publicly

Who are you?

Thank you for your feedback - we very much appreciate it!

See also

Back to top